Originally doing business grounded in a license of technology from Arrowhead Research based in nanoparticle-based drug candidates, Enumeral Biomedical Corp. is focused on discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. In August, 2014 merger wasannounced between Enumeral Biomedical Corp. and a subsidiary of Enumeral Biomedical Holdings, Inc., formerly known as Cerulean Group, Inc. Coinciding with the merger, Enumeral closed on a private placement financing and an achieved IPO with shares trading under the symbol ENUM.The firm uses its microengraving (nanotechnology-enabled) process to address opportunities in immunology including therapeutic discovery, immune profiling and personalized medicine. Its proprietary microengraving technology creates high-density bio-chip microarrays of the secreted products of single human cells derived from patient samples to provide analysis of antibody affinity and specificity, as well as cytokine profiles and T-cell functionality. The company was formerly known as Enumeral Technologies, Inc., and changed its name to Enumeral Biomedical Corp. in November 2010.
